Preclinical studies in rats using angiotensinogen siRNA in preeclampsia models did not demonstrate adverse effects on offspring, nor was placental transfer detected; however, these findings are insufficient to establish safety in humans. The gene discussed is AGT; the disease is preeclampsia.